Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Emergency room visits attributed to popular weight loss drugs such as Ozempic and Wegovy remain quite rare overall, but do ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Danish pharmaceutical company Novo Nordisk plans to introduce its weight-loss drug Wegovy in India earlier than planned to ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in ...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S NVO, reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion ...

In stark contrast to the struggles of Bitcoin and Tesla, Novo Nordisk has emerged victorious, reporting a staggering $9 billion in income from its weight loss drug sales. This figure underscores the ...